National Health (Pharmaceutical Benefits–Early supply) Amendment (September Update) Specification 2026

Contents

1. Name #

(1)This instrument is the National Health (Pharmaceutical Benefits–Early Supply) Amendment (September Update) Specification 2026.

(2)This instrument may also be cited as PB 100 of 2026.

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 September 2026	1 September 2026

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3. Authority #

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4. Schedules #

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

[1] Schedule 1, after entry for Dapsone in the form Tablet 25 mg

insert:

Dapsone

Tablet 25 mg (s19A)

100

[2] Schedule 1, after entry for Estradiol in the form Transdermal patches 390 micrograms, 8

insert:

Estradiol

Transdermal patches 390 micrograms, 8 (s19A)

[3] Schedule 1, after entry for Estradiol in the form Transdermal patches 780 micrograms, 8

insert:

Estradiol

Transdermal patches 780 micrograms, 8 (s19A)

[4] Schedule 1, entries for Momelotinib

(a) omit:

Momelotinib

Tablet 100 mg (as dihydrochloride monohydrate)

(b) omit:

Momelotinib

Tablet 150 mg (as dihydrochloride monohydrate)

Momelotinib

Tablet 200 mg (as dihydrochloride monohydrate)

[5] Schedule 1, entries for Ruxolitinib

(a) omit:

Ruxolitinib

Tablet 5 mg

112

(b) omit:

Ruxolitinib

Tablet 10 mg

Ruxolitinib

Tablet 15 mg

(d) omit:

Ruxolitinib

Tablet 20 mg

Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.

National Health (Pharmaceutical Benefits–Early supply) Amendment (September Update) Specification 2026

1. Name #

2. Commencement #

3. Authority #

4. Schedules #

Key facts

History · 1 version

1. Name #

2. Commencement #

3. Authority #

4. Schedules #